United States Patent 10,005,761: Encorafenib and Binimetinib Cancer-Treatment Claims
U.S. Patent No. 10,005,761 covers methods of treating cancer with encorafenib, alone or with another anticancer agent. Its commercially important claims cover the combination of encorafenib and binimetinib, including fixed, non-fixed, concurrent, and sequential administration for BRAF V600E-mutant melanoma and colorectal cancer. The patent issued June 26, 2018, and is assigned to Array BioPharma Inc., now within Pfizer.
The patent is a method-of-use patent. It does not claim the encorafenib molecule as such, a tablet formulation, a manufacturing process, or binimetinib as a standalone product.
What drug does U.S. Patent 10,005,761 protect?
The chemical compound identified in the claims is encorafenib, marketed as Braftovi. Encorafenib is a selective BRAF kinase inhibitor. The additional agent identified as ARRY-438162 is binimetinib, marketed as Mektovi, a MEK1/2 inhibitor.
| Claim element |
Commercial identity |
| Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate |
Encorafenib |
| ARRY-438162 |
Binimetinib |
| BRAF V600E-mutant melanoma |
FDA-approved Braftovi/Mektovi indication |
| BRAF V600E-mutant colorectal carcinoma |
Claimed subject matter; not the principal FDA-approved Braftovi/Mektovi indication |
The FDA approved Braftovi in combination with Mektovi for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in June 2018. The approval was based on the COLUMBUS clinical program. The FDA later approved Braftovi with cetuximab, with or without binimetinib, for previously treated metastatic colorectal cancer with a BRAF V600E mutation in 2020.[1]
What is the scope of the issued claims?
The claims have four principal layers:
- Encorafenib treatment of cancer.
- Treatment of specified tumor types.
- Encorafenib treatment of BRAF V600E-mutant melanoma or colorectal cancer.
- Encorafenib combined with binimetinib, including specific administration formats and schedules.
Claim 1: broad encorafenib monotherapy method
Claim 1 covers administering a therapeutically effective amount of encorafenib, or a pharmaceutically acceptable salt, to a patient with cancer.
The claim does not require:
- A particular dose.
- A particular route of administration.
- A specific formulation.
- A specific treatment duration.
- A BRAF mutation.
- Combination therapy.
- A particular response endpoint.
Its breadth is limited by the requirement that the accused conduct be treatment of cancer and involve administration of the claimed encorafenib compound or salt.
Claims 2 through 7: tumor and biomarker limitations
Claim 2 narrows claim 1 to listed cancers, including lung, pancreatic, bladder, colon, prostate, thyroid, melanoma, ovarian, ocular, liver, biliary tract and nervous-system tumors, as well as myeloid disorders and adenomas.
Claims 3 through 5 narrow the subject matter to melanoma, metastatic melanoma and BRAF V600E-mutant melanoma. Claims 6 and 7 cover colon carcinoma and BRAF V600E-mutant colon carcinoma.
The most commercially relevant monotherapy claims are therefore claims 4, 5 and 7. They target metastatic melanoma and BRAF V600E-driven disease, where BRAF inhibition is clinically and commercially established.
Claims 8 through 13: combination treatment
Claim 8 covers encorafenib administered with an additional therapeutic agent. Claim 9 limits the additional agent to an anticancer compound. Claim 10 identifies a broad group of targets, including:
- Another RAF inhibitor.
- MEK.
- mTOR.
- HSP90.
- AKT.
- PI3K.
- CDK9.
- PAK.
- Protein kinase C.
- MAP kinase.
- MAPK kinase.
- ERK.
Claim 11 narrows the combination to a MEK inhibitor. Claim 12 provides a list of named compounds. Claim 13 narrows the MEK inhibitor to ARRY-438162, or binimetinib.
Claim 13 is the key genus-to-species transition in the patent. Claims 10 and 11 could reach combinations involving other pathway inhibitors, but claim 13 is directed specifically to encorafenib plus binimetinib.
Which claims cover Braftovi and Mektovi combination therapy?
Claims 13 through 28 cover the encorafenib-binimetinib combination. The principal claim categories are summarized below.
| Claims |
Subject matter |
| 13 |
Encorafenib plus binimetinib |
| 14 |
Fixed combination |
| 15 |
Non-fixed combination |
| 16 |
Sequential administration under the fixed-combination branch |
| 17 |
Concurrent administration under the fixed-combination branch |
| 18-20 |
Combination treatment of melanoma, including metastatic and BRAF V600E-mutant melanoma |
| 21-23 |
Non-fixed, sequential or fixed combination for melanoma |
| 24-28 |
Combination treatment of colon carcinoma, including BRAF V600E-mutant disease |
The commercially important claims are claims 18 through 23 because they directly address melanoma, including metastatic and BRAF V600E-mutant melanoma. Claims 24 through 28 extend the combination claims to BRAF V600E-mutant colorectal cancer.
How do the fixed and non-fixed combination claims differ?
A fixed combination normally refers to two active ingredients provided together in a single dosage form or predetermined combination. A non-fixed combination generally refers to separate products administered as part of the same therapeutic regimen.
The patent claims both structures:
- Claim 14: fixed encorafenib-binimetinib combination.
- Claim 15: non-fixed encorafenib-binimetinib combination.
- Claim 17: concurrent administration.
- Claims 16 and 22: sequential administration.
The claim set contains apparent dependency and drafting tension. Claim 16 depends on claim 14 while requiring sequential administration. Claim 22 depends on claim 21 and requires sequential administration, while claim 21 depends on claim 18 and recites a non-fixed combination. These limitations may create claim-construction issues concerning whether "fixed combination" describes the product form, the treatment regimen, or both.
A court would assess the claims with the specification and prosecution history. The apparent tension does not automatically invalidate the claims, but it can affect scope and enforceability.
What cancers are protected by the patent?
The patent has broad oncology language, but its practical value is concentrated in BRAF-driven tumors.
| Disease setting |
Claim coverage |
Commercial relevance |
| Melanoma |
Claims 2-5, 18-23 |
High |
| Metastatic melanoma |
Claims 4, 19 |
High |
| BRAF V600E-mutant melanoma |
Claims 5, 20 |
High |
| Colon carcinoma |
Claims 2, 6-7, 24-28 |
High for claimed use |
| BRAF V600E-mutant colon carcinoma |
Claims 7, 25-28 |
High for biomarker-selected use |
| Lung, pancreatic, bladder and other listed tumors |
Claim 2 |
Dependent on factual treatment use and claim construction |
| Other anticancer combination settings |
Claims 8-12 |
Variable |
The claims do not require that the cancer be BRAF-mutant except where the dependent claims expressly add that limitation. A generic or competing encorafenib product used in a non-mutant cancer setting could face different infringement questions than one promoted or labeled for BRAF V600E-mutant melanoma.
What patents protect encorafenib and the Braftovi franchise?
U.S. Patent 10,005,761 is one component of the encorafenib patent estate. The broader estate has included separate patent families directed to:
- The encorafenib compound.
- Salt and crystalline forms.
- Pharmaceutical compositions.
- Combination treatment with binimetinib.
- Treatment of BRAF-mutant melanoma.
- Treatment of BRAF-mutant colorectal cancer.
- Drug combinations involving EGFR inhibition.
The relevant distinction is between molecule patents and use patents.
| Patent category |
Typical protection |
Relevance to generic entry |
| Compound patent |
Encorafenib chemical structure |
Usually the strongest barrier if unexpired |
| Salt or solid-form patent |
Specific pharmaceutical form |
Can restrict formulation substitution |
| Formulation patent |
Dosage form, excipient system or release profile |
Relevant to ANDA product design |
| Combination patent |
Encorafenib plus binimetinib |
Relevant to coadministration and labeling |
| Method-of-use patent |
Specific cancer, mutation or regimen |
Relevant to label carve-outs and induced infringement |
| Manufacturing patent |
Synthetic route or intermediates |
Relevant where the route is commercially necessary |
The supplied patent claims do not establish whether every other patent in the family remains enforceable, whether any patent term adjustment applies, or whether the patents are listed in the FDA Orange Book. Those determinations require the current USPTO, FDA and court records.
When does U.S. Patent 10,005,761 expire?
The patent issued June 26, 2018. Its statutory term is generally measured from the earliest effective nonprovisional filing date for the claimed invention, not from the issue date.[2] A precise expiration date therefore depends on the priority chain and any patent-term adjustment.
The patent appears to belong to the early encorafenib/binimetinib development period, placing ordinary statutory expiry approximately in the 2030-2031 period before any adjustment. The issue date alone cannot be used to calculate the expiration date.
Patent-term extension under 35 U.S.C. § 156 is generally associated with regulatory review of a product patent and does not automatically apply to every method-of-use patent. Any patent-term adjustment under 35 U.S.C. § 154 must be checked in the issued patent and USPTO Patent Center records.[2,3]
What is the Orange Book status of U.S. Patent 10,005,761?
The Orange Book question must be analyzed separately for Braftovi and Mektovi.
Braftovi is encorafenib. Mektovi is binimetinib. A patent may be relevant to the Braftovi product even when its claims require administration with binimetinib, but listing depends on FDA Orange Book rules and the patent owner’s certification to FDA.
A method-of-use patent can be listed if it claims an approved method of using the drug. FDA listing does not determine validity or infringement. It affects the timing and litigation consequences of an abbreviated new drug application, including Paragraph IV certification and the potential 30-month stay under the Hatch-Waxman Act.[4]
The supplied claim text alone does not establish the current Orange Book listing status of U.S. Patent 10,005,761.
Are there Paragraph IV challenges or generic litigation?
A Paragraph IV certification is an ANDA applicant’s assertion that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. The certification can trigger patent litigation under 35 U.S.C. § 271(e)(2).[4]
For U.S. Patent 10,005,761, the claim text does not identify:
- An ANDA applicant.
- A Paragraph IV notice letter.
- A district-court complaint.
- A settlement agreement.
- A final judgment.
- A covenant not to sue.
- An approved generic product.
The existence of a Paragraph IV case cannot be inferred from the patent’s issuance or from Braftovi’s commercial status. A current litigation determination requires a search of FDA Paragraph IV notices, PACER, district-court dockets and the Federal Court of Appeals records.
How strong is the patent estate?
The patent has meaningful commercial value because it covers the clinically important BRAF/MEK combination rather than only a broad, undifferentiated cancer use.
Strengths
- Claims specifically identify encorafenib.
- Claims identify binimetinib by development code.
- Claims cover melanoma and metastatic melanoma.
- Claims cover BRAF V600E-mutant disease.
- Claims reach both fixed and non-fixed combinations.
- Claims include concurrent and sequential administration.
- Claims cover colorectal cancer, a separate commercial indication.
Vulnerabilities
- Combination claims may face obviousness challenges based on prior BRAF/MEK combination studies.
- Broad cancer claims may face written-description and enablement challenges if the specification does not support the full disease list.
- The fixed-versus-sequential dependency structure may create indefiniteness or claim-construction disputes.
- The listed MEK-inhibitor group includes compounds that may not uniformly be MEK inhibitors, creating potential scope and drafting issues.
- Method claims depend on actual administration and treatment conduct, which can complicate infringement proof.
- Label carve-outs may reduce direct inducement risk for an ANDA applicant if the patented use can be omitted from the proposed label.
The strongest practical claims are likely the narrower encorafenib-plus-binimetinib claims directed to BRAF V600E-mutant melanoma, particularly where the approved label and commercial promotion correspond to the claimed regimen.
What generic entry scenarios exist?
Scenario 1: molecule or composition patent remains blocking
A generic applicant may need to challenge the core encorafenib patent or wait for its expiry. U.S. Patent 10,005,761 would then be an additional use-patent issue rather than the only barrier.
Scenario 2: skinny-label entry
If only method claims remain listed, an ANDA applicant may seek approval for non-patented uses while carving out melanoma, BRAF V600E-mutant disease or combination use. The feasibility depends on the approved labeling, remaining Orange Book listings and the scope of the proposed carve-out.
Scenario 3: Paragraph IV litigation
A Paragraph IV applicant could challenge validity, enforceability or infringement. Key defenses would likely include obviousness based on BRAF/MEK combination art, lack of written description for the full disease and combination scope, indefiniteness arising from claim dependencies, and non-infringement based on a non-infringing label or regimen.
Scenario 4: authorized or licensed entry
A settlement could permit entry before patent expiry under agreed conditions. No settlement terms are established by the supplied record.
How does this patent compare with a formulation patent?
U.S. Patent 10,005,761 is a treatment-method patent. It does not prevent every manufacture or sale of encorafenib. Its infringement theory generally requires proof that a party made, used, offered, sold or induced conduct falling within the claimed treatment method.
A formulation patent can be easier to assert against an ANDA product if the generic necessarily uses the claimed formulation. A method patent may be more vulnerable to a skinny-label strategy, but it can remain commercially important when the patented use is the principal or unavoidable indication.
Key Takeaways
- U.S. Patent 10,005,761 covers encorafenib treatment methods.
- The patent’s key commercial claims cover encorafenib plus binimetinib.
- Claims reach fixed, non-fixed, concurrent and sequential administration.
- BRAF V600E-mutant melanoma, metastatic melanoma and colorectal cancer are central claimed settings.
- ARRY-438162 is binimetinib, the MEK inhibitor marketed as Mektovi.
- The patent is not a standalone encorafenib compound patent or a binimetinib composition patent.
- The likely statutory term falls around 2030-2031, subject to the priority chain and patent-term adjustment.
- Orange Book listing, Paragraph IV activity, litigation and settlement status cannot be determined from the claim text alone.
- The strongest enforceability questions concern obviousness, written description, enablement and the fixed/sequential claim dependencies.
- Generic entry risk depends on the separate encorafenib composition estate, remaining Orange Book patents, approved-label carve-outs and any Paragraph IV litigation.
FAQs
Does U.S. Patent 10,005,761 cover Braftovi alone?
Yes. Claims 1 through 7 cover methods using encorafenib alone for specified cancer settings. The later claims cover combination therapy.
Does the patent cover Mektovi alone?
No. The claims require encorafenib. Binimetinib appears as an additional agent in the combination claims and is not claimed as a standalone treatment.
Does the patent require a BRAF mutation?
No. Claims 1 through 4 and several combination claims do not require a BRAF mutation. Claims 5, 7, 20 and 25 specifically add BRAF V600E mutation limitations.
Does a fixed combination require one tablet containing both drugs?
Not necessarily. The final interpretation depends on the patent specification and prosecution history. The claim language distinguishes fixed, non-fixed, concurrent and sequential administration, but the dependencies create construction issues.
Can a generic sell encorafenib for an unclaimed cancer indication?
Potentially, but the answer depends on the remaining compound, formulation and method patents, the proposed label, promotional conduct and whether the use would induce infringement of an unexpired claim.
References
-
U.S. Food and Drug Administration. (2018). FDA approves encorafenib with binimetinib for metastatic melanoma with a BRAF mutation. FDA.
-
United States Code. (2023). 35 U.S.C. §§ 154, 156, and 271.
-
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance. USPTO.
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
-
United States Patent and Trademark Office. (2018). U.S. Patent No. 10,005,761: Methods of treating cancer using a BRAF inhibitor and a MEK inhibitor. USPTO.
